Genmab — Januar 2026
-
If control patients progress faster (as PFS suggests), they exit the trial sooner and start potent subsequent therapies while their disease burden is lower and they're healthier. This can extend their survival more than if they progressed later (as in the epcoritamab arm, where delayed progression means later rescues, potentially when patients are sicker or have more resistant disease).
-
Det er sådan noget her der er så træls ved Genmab aktien..... En frygtelig masse gode nyheder igennem lang tid. Men aktien belønner det af uransaglige grunde ikke, - og når så disse uundgåelige dårlige nyheder kommer, så får det konsekvenser for kursen.... Det er ufatteligt at aktien skal ligge og rode under 15 i P/E...... Derr blev omsat over 5mill i US efter nyheden på omkring 2 timer... - Der var da nogle stykker der vil ud!
-
I mine øjne vil jeg ikke give dig ret @Sukkeralf ..... Der er en faktor der har gjort den store forskel og det er købet af Merus.... Er klar over Darzalex patent udløb om 4-5år, men med de godter Genmab i tiden skilter med. - Der burde være en langt højere forventning til at fremtiden ser lys ud - hvilket burde spejle sig i langt højere grad i
P/E værdien -
Med hensyn til Darzalex så er det jo faste indtægter, mens alle de tiltag Genmab laver giver forhåbninger om indtægter fremadrettet, men vi ved jo ikke om de kommer, hvor meget det bliver og hvor hurtigt. Og går epco, rita og peto igennem så skal det nok blive godt, men det har jo stadig meget lange udsigter - så i takt med positive fase III kommer i hus, så skal kursen nok stige stille og roligt.
-
Can epcoritamab reshape salvage DLBCL care? Genmab’s Phase 3 data brings regulatory momentum https://pharmadevicenews.com/can-epcoritamab-reshape-salvage-dlbcl-care-genmabs-phase-3-data-brings-regulatory-momentum/
-
Godmorgen
-
just to put friday's price action into perspective; expert Hutchings compares the data to STARGLO https://x.com/DocHutchings/status/2012577901636362506 , which is Glofitamab plus chemo, while the epco DLBCL-1 data is monotherapy and has a different population. i really don't think you can do that
-
Teclistamab Monotherapy Improves OS and PFS Over SOC in Relapsed/Refractory Multiple Myeloma -reducing disease progression or death risk by 71% and death risk by 40%. -the Independent Data Monitoring Committee recommended unblinding the trial based on the strength of the results.
https://www.onclive.com/view/teclistamab-monotherapy-improves-os-and-pfs-over-soc-in-relapsed-refractory-multiple-myeloma -
Godmorgen
-
Genmab viser igen gode takter med kræftmiddel i fase 3-studie https://proinvestor.com/investornyt/1404446/genmab-viser-igen-gode-takter-med-kraeftmiddel-i-fase-3-studie
. I try to Buy European given the current political climate, but unfortunately we are dangerously behind here on these things...Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind